Interview with Oncology Venture Sweden AB and Medical Prognosis Institute A/S in ‘Millionærklubben’
The Danish radio 24syv made an extensive interview with Oncology Venture Sweden AB (“Oncology Venture”) and Medical Prognosis Institute A/S (“MPI”) Tuesday 21st March 2017.
CEO Peter Buhl Jensen explains about Oncology Venture and drug development and COO Ulla Hald Buhl explains about Medical Prognosis Institute.
To hear the interview with Oncology Venture and MPI, please visit:
http://www.radio24syv.dk/programmer/millionaerklubben/16358789/oncology-venture-klar-til-ny-emission
For further information about Oncology Venture, please contact:
| Ulla Hald Buhl, COO and Chief IR & CommunicationsMobile: +45 2170 1049uhb@oncologyventure.com | or | Peter Buhl Jensen, CEOMobile: +45 21 60 89 22E-mail: pbj@oncologyventure.com |
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.
Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.